Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has initiated trials of the lymphotoxin beta fusion protein in two key RA patient populations.